Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aptose Biosciences Ord Shs T.APS

Alternate Symbol(s):  APTOF

Healthcare Biotechnology
Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:APS)

Aptose Reports First Quarter 2025 Results

GlobeNewswire 5 days ago

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

GlobeNewswire 8 days ago

Aptose Announces Auditor Not Standing for Re-Appointment

GlobeNewswire April 23, 2025

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 23, 2025

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

GlobeNewswire April 1, 2025

Aptose Reports Year End 2024 Results and Corporate Highlights

GlobeNewswire March 28, 2025

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

GlobeNewswire March 17, 2025

Aptose's leukemia drug cleared to double clinical trial dose

Trevor Abes  February 20, 2025

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

GlobeNewswire February 20, 2025
View More News ››

Opinion & Analysis (TSX:APS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:APS)

Very undervalued.

TUS will be a game changer treating AML. It already proven to be safe and efficacy at 40 mg dose , very eager to see the results at 80 mg...
Alex1726 - April 17, 2025

NASDAQ decides to remove shares from listing...

Said this is due to non compliance of equity... ny savvier trader than me can explain? Thanks in advance
Palindrome808 - April 1, 2025

E-MAIL TO APTOSE BIOSCIENCES - INVESTOR RELATIONS

  Mrs. Pietropaolo,   I have been a shareholder of both IMUTEC PHARMA, which name changed to LORUS...
BLUEBERRY5 - February 27, 2025

RE:APTO....19 f'king cents now

Sub 19 now ; )
Iseneschal - February 20, 2025

APTO....19 f'king cents now

No likes  for me ?????
Iseneschal - February 20, 2025

APTO....not to bags !

It got to 25 cents....LoL Lots of new Bagholders....RS coming 
Iseneschal - February 20, 2025
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Publicly listed in Canada (CSE: FNQ) with quoted symbols on Nasdaq (OTC: FNQQF) and the Frankfurt Stock Exchange (Frankfurt ...
View More »